Printer Friendly

Just Published: "House Dust Mite Allergy - Pipeline Review, H1 2016".

[USPRwire, Fri Apr 01 2016] Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H1 2016', provides an overview of the House Dust Mite Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Full Report Details at


Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Report Scope

* The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy

* The report reviews pipeline therapeutics for House Dust Mite Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

* The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

* The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

* The report reviews key players involved House Dust Mite Allergy therapeutics and enlists all their major and minor projects

* The report assesses House Dust Mite Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

* The report summarizes all the dormant and discontinued pipeline projects

Copyright [c] 2016 USPRwire Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2016 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Date:Apr 1, 2016
Previous Article:Bulgaria Pharmaceuticals & Healthcare Report Q2 2016 - New Market Report.
Next Article:New Market Research Report: Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters